Author: Customer Service

Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million) Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of Lisaftoclax since launch during last five months of 2025 were US$10.1 million (RMB 70.6 million) Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA Chinese (Mandarin) investor event with simultaneous conference call and webcast at 10:00 am HKT on March 26, 2026 / 10:00 pm EDT on March 25, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on March 26, 2026ROCKVILLE, Md. and SUZHOU, China, March 25, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as “Ascentage...

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results

Written by Customer Service on March 25, 2026. Posted in Public Companies.

TORONTO, March 25, 2026 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and fourth quarter financial results for the three and twelve months ended December 31st, 2025, before markets open on Monday, March 30th, 2026. MediPharm Labs executive management team will also host a conference call and webcast on Monday March 30th, 2026, at 10:00 a.m. (Eastern time) to discuss the Company’s financial results. Conference Call Dial in Details:North America Toll-Free: (888) 330-2454International Toll: +1 (240) 789-2714Conference ID: 4921762Participants are asked to dial in approximately 15 minutes before the...

G Mining Ventures Reports Q4 and Full-Year 2025 Results; First Full Year of Commercial Production at Tocantinzinho Drives Strong Cash Flow Generation

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

BROSSARD, Quebec, March 25, 2026 (GLOBE NEWSWIRE) — G Mining Ventures Corp. (“GMIN” or the “Corporation”) (TSX:GMIN, OTCQX:GMINF) today reported its financial and operating results for the fourth quarter and full year ended December 31, 2025. Unless otherwise indicated, all dollar amounts are in U.S. dollars. “Tocantinzinho completed its first full year of commercial production in 2025, delivering consistent operating performance with production, recoveries and costs in line with expectations,” said Louis-Pierre Gignac, President and Chief Executive Officer. Production, costs and recoveries largely met or exceeded guidance, underscoring the asset’s reliability and operational discipline. The operation generated $255 million in free cash flow, strengthening our balance sheet while funding the advancement of Oko West. Fourth quarter...

Press release – Fiscal-year 2025 results: AFL Group delivers record results, doubling its net profit

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

Press release26 March, 2026 Fiscal-year 2025 results: AFL Group delivers record results, doubling its net profit Dynamic activity and record results in 2025 Key figures as at 31/12/2025 (IFRS) AFL Group1 (consolidated – IFRS) AFL2 (consolidated – IFRS) Net banking income €30.8m (+28% Year-on-Year – YoY) €30.7m (+29% YoY)Operating expenses €17.5m (+8% YoY) €17.5m (+9% YoY)Gross operating income €13.3m (+69% YoY) €13.3m (+70% YoY)Net income before tax €13.3m (+78% YoY) €13.3m (+79% YoY)Net profit €10.8m (+100% YoY) €10.8m (+100% YoY)Cost income ratio3 64.4% (vs. 67.8% on 31/12/2024) 64.3% (vs. 67.7% on 31/12/2024)Record fiscal-year resultsNet banking income strongly grew broadly in line with the increase in outstanding loans, which exceeded €10 B as at 31 December, 2025. Gross...

2025 ANNUAL REPORT: UNIBAIL-RODAMCO-WESTFIELD N.V. (EURONEXT: URW)

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

Amsterdam, March 25, 2026 Press Release 2025 ANNUAL REPORT: UNIBAIL-RODAMCO-WESTFIELD N.V. (EURONEXT: URW) Unibail-Rodamco-Westfield N.V. (“URW NV” or the “Company”) today released its 2025 Annual Report. The Company’s 2025 Annual Report, including the Management Board Report and the audited Financial Statements for the fiscal year ended December 31, 2025, can be found on URW N.V. website (section Investors). URW NV’s portfolio consists of assets in the United States and The Netherlands. URW NV and its consolidated entities, together with Unibail-Rodamco-Westfield SE (“URW SE”) and its consolidated entities, form Unibail-Rodamco-Westfield Group (“URW”). URW SE consolidates URW NV and its controlled undertakings. The 2025 Universal Registration Document of URW SE, including the accounts, provides a comprehensive overview of URW and is available...

Liberty Gold Reports Year-End 2025 Financial and Operating Results

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) — Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) (“Liberty Gold” or the “Company”), is pleased to announce its financial and operating results for the fiscal year ended December 31, 2025. All amounts are presented in United States dollars unless otherwise stated. RECENT PROJECT HIGHLIGHTS – BLACK PINE During 2025 and early 2026, Liberty Gold advanced the Black Pine Gold Project (“Black Pine” or the “Project”) through resource growth, commencement of a feasibility study, and key federal permitting milestones, while also executing strategic corporate initiatives. At the Black Pine project in IdahoOn March 23, 20261, we announced that a coordinated federal and state permitting schedule has been posted to the United States government permitting dashboard, pursuant...

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Written by Customer Service on March 25, 2026. Posted in Public Companies.

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on March 16, 2026 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company’s ability to continue as a going concern. See further discussion in footnote 1 to the Company’s consolidated financial statements included in the Company’s Annual Report on Form 10-K. This announcement is made pursuant to NYSE American...

JBS reports record revenue of US$ 86.2 billion and closes 2025 with US$ 2 billion in net income

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

Strong performance across Pilgrim’s Pride, JBS Australia and Seara showcases breadth of the JBS portfolio; earnings per share of US$ 1.89 reflect 15% growth GREELEY, Colo., March 25, 2026 (GLOBE NEWSWIRE) — JBS today announced financial results for the fourth quarter and full year ended December 31, 2025, which included record net revenue of US$ 86 billion, an increase of 12% compared to 2024. Net income for the full year 2025 grew 13%, reaching US$ 2 billion. The strong performance was driven primarily by Pilgrim’s Pride Corporation, JBS Australia and Seara, all of which delivered significant organic growth and value creation. The results underscore the resilience of the company’s global multiprotein and multiplatform strategy across diverse market environments. JBS reported adjusted EBITDA under IFRS of US$ 6.8 billion, with an...

XORTX Announces Share Consolidation

Written by Customer Service on March 25, 2026. Posted in Public Companies.

CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company’s board of directors has approved consolidating (the “Consolidation”) its common shares (“Shares”) on the basis of one post-consolidation Share for every five pre-consolidation Shares, effective March 27, 2025 (the “Effective Date”). The Company will not undergo a name change in connection with the Consolidation. The Consolidation has been approved by the TSX Venture Exchange (the “TSXV”) and follows approval of a consolidation of the Shares on the basis of a range of up to five pre-consolidation Shares for every...

Golar LNG Limited announces strategic review to maximize stakeholder value and appoints Goldman Sachs as financial advisor

Written by Customer Service on March 25, 2026. Posted in Public Companies.

Golar LNG Limited (NASDAQ: GLNG) (“Golar” or the “Company”) today announced its Board of Directors has initiated a formal process to evaluate strategic alternatives for the Company. As previewed on the 4th Quarter 2025 results, this review aims to accelerate the FLNG growth pipeline and maximize shareholder value, reflecting Golar’s successful transition into a high-growth, pure-play Floating Liquefied Natural Gas (FLNG) company. To support this process, the Company has appointed Goldman Sachs International as its financial advisor. The strategic review will include a comprehensive evaluation of the Company’s platform, including its industry-leading FLNG technology, long-term contract backlog, and growth pipeline. Potential alternatives to be explored include, but are not limited to, a sale of the Company, a merger or other business combination,...

Author: Customer Service

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals